Status:
COMPLETED
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
Lead Sponsor:
EuBiologics Co.,Ltd
Conditions:
Infection, Meningococcal
Eligibility:
All Genders
19-55 years
Phase:
PHASE1
Brief Summary
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine
Eligibility Criteria
Inclusion
- Subjects 19 to 55 years of age
- Written informed consent
- Available for all visits and telephone calls scheduled for the study
Exclusion
- Previous or suspected disease caused by N. meningitidis
- Household and/or intimate exposure to an individual with culture-proven N. meinigitidis infection within 60 days prior to screening
- Serious acute, chronic or progressive disease as determined by investigator
- History of alcohol or substance abuse
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04714229
Start Date
September 1 2020
End Date
September 1 2021
Last Update
October 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea